| |
| Important Safety Information for Helixate®FS |
| |
| Helixate® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor. |
| |
| Helixate® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations of known sensitivity to mouse or hamster protein. |
| |
| Adverse events are generally minor. The most common adverse events include injection-site reactions, dizziness, and rash. |
| |
| For more information about Helixate® FS, please see . |
